Clinical Trial Update: Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of PG2 for idiopathic thrombocytopenic purpura has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• PG2

Snippet

Sponsor: PhytoHealth Corporation | Conditions: Idiopathic Thrombocytopenic Purpura (ITP) | Phase 2 | Status: COMPLETED